ABC drug transporters: Hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2

Pharmacogenomics

Volumn 2, Issue 1, 2001, Pages 51-64

  Kerb, R ^a   Hoffmeyer, S ^a   Brinkmann, U ^a  

^a Epidauros Biotechnologie AG   (Germany)

Author keywords

Detoxification; Drug metabolism; Drug uptake; Hereditary polymorphisms; Multi drug resistance; P glycoprotein; Pharmacogenetics

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE BINDING CASSETTE PROTEIN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CEFAZOLIN; CHLORAMBUCIL; CYCLOSPORIN A; DACTINOMYCIN; DAUNORUBICIN; DIGOXIN; DILTIAZEM; DOMPERIDONE; DOXORUBICIN; FLUPHENAZINE; GLYCOPROTEIN P; INDINAVIR; LOPERAMIDE; MEMBRANE PROTEIN; METHOTREXATE; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN; NICARDIPINE; PHENYTOIN; QUINIDINE; TACROLIMUS; TAMOXIFEN; TERFENADINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

ADVERSE DRUG REACTION; CENTRAL NERVOUS SYSTEM; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG CONCENTRATION; DRUG DISPOSITION; DRUG INTERACTION; DRUG RESISTANCE; DRUG TRANSPORT; EFFUSION; GENETIC VARIABILITY; GENETICS; HUMAN; PHARMACOLOGY; PHENOTYPE; REVIEW;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE; GENES, MDR; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; VARIATION (GENETICS);

EID: 0034936354     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.2.1.51     Document Type: Review

References (128)

1. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
2. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
3. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs
4. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
5. Isolation and expression of a complementary DNA that confers multidrug resistance
6. A general pattern for substrate recognition by P-glycoprotein
7. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia
8. Pharmacological issues relating to viral resistance
9. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
10. p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy
11. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia
12. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response
13. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy
14. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy
15. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2 and lung resistance protein as prognostic factors in ovarian carcinoma
16. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: Results of a 6-year prospective study
17. P-glycoprotein-mediated multidrug resistance: Experimental and clinical strategies for its reversal
18. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers
19. Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney
20. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
21. Clinical trials of P-glycoprotein reversal in solid tumours
22. Modulators of multidrug resistance. Preclinical studies
23. Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: Molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs
24. Competitive and non-competitive inhibition of the multidrugresistance-associated P-glycoprotein ATPase-further experimental evidence for a multisite model
25. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells
26. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state
27. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
28. Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin and vinblastine
29. The multidrug resistance protein family
30. A family of drug transporters: The multidrug resistance-associated proteins
31. P-glycoprotein and multidrug resistance
32. Structural, mechanistic and clinical aspects of MRP1
33. Molecular mechanisms of multidrug resistance in cancer chemotherapy
34. Importance of glutathione and associated enzymes in drug response
35. Glutathione-related mechanisms in cellular resistance to anticancer drugs
36. Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione
37. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA
38. The function of the multidrug resistance proteins (MRP and cMRP) in drug conjugate transport and hepatobiliary excretion
39. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2
40. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2
41. Export pumps for glutathione S-conjugates
42. Export pumps for anionic conjugates encoded by MRP genes
43. Hepatic secretion of conjugated drugs and endogenous substances
44. Characterization of vincristine transport by the M(r) 190, 000 multidrug resistance protein (MRP): Evidence for cotransport with reduced glutathione
45. Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in carcinoma cells
46. Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP
47. Do cMOAT (MRP2), other MRP homologues and LRP play a role in MDR?
48. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells
49. Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes
50. Localization, substrate specificity and drug resistance conferred by conjugate export pumps of the MRP family
51. Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity and MRP2-mediated drug resistance
52. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1
53. Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells
54. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1
55. Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport
56. Transport of glutathione, glucuronate and sulfate conjugates by the MRP gene-encoded conjugate export pump
57. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates
58. Identification of the biosynthetic leukotriene C4 export pump in murine mastocytoma cells as a homolog of the multidrug-resistance protein
59. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump
60. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2
61. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2
62. ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene
63. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
64. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation
65. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues
66. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein
67. Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues
68. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier
69. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP
70. Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA
71. An inventory of the human ABC proteins
72. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines
73. The human multidrug resistance protein 2 gene: Functional characterization of the 5′-flanking region and expression in hepatic cells
74. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome
75. Impaired Protein Maturation of the Conjugate Export Pump Multidrug Resistance Protein 2 as a Consequence of a Deletion Mutation in Dubin-Johnson Syndrome
76. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
77. Multidrug resistance and the role of P-glycoprotein knockout mice
78. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted
79. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption
80. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
81. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein
82. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
83. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein- deficient Mice
84. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice
85. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A
86. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
87. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
88. The pharmacological role of P-glycoprotein in the intestinal epithelium
89. Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein
90. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
91. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
92. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgesic drug
93. Biochemical, cellular and pharmacological aspects of the multidrug transporter
94. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance
95. Characterization of the human multidrug resistance protein containing mutations in the ATP-binding cassette signature region
96. Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity
97. The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface
98. Drug-stimulated ATPase activity of human P-glycoprotein is blocked by disulfide cross-linking between the nucleotide-binding sites
99. Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein
100. Drug-stimulated nucleotide trapping in the human multidrug transporter MDR1. Cooperation of the nucleotide binding domains
101. Both P-glycoprotein nucleotide-binding sites are catalytically active
102. Functional analysis of the nucleotide binding domains of the multidrug resistance protein (MRP)
103. Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12
104. Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdr1b
105. Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine
106. Pseudomonas exotoxin fusion proteins are potent immunogens for raising antibodies against P-glycoprotein
107. Characterization of the azidopine and vinblastine binding site of P-glycoprotein
108. Localization of the forskolin labeling sites to both halves of P-glycoprotein: Similarity of the sites labeled by forskolin and prazosin
109. Genetic polymorphism in MDR-1: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines and human tumors
110. Photoaffinity labeling of human P-glycoprotein: Effect of modulator interaction and ATP hydrolysis on substrate binding
111. Functional polymorphisms of the human multidrugresistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
112. Chronic idiopathic jaundice with unidentified pigment in liver cells: A new clinicopathologic entity with report of 12 cases
113. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome
114. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome
115. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome
116. Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome
117. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
118. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney
119. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1)
120. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
121. HIV-1 protease inhibitors and the MDR1 multidrug transporter
122. Update: Genetic polymorphism of drug metabolizing enzymes in humans
123. Polymorphisms in drug-metabolizing enzymes: What is their clinical relevance and why do they exist?
124. Molecular genetics of cancer susceptibility
125. How to manage individualized drug therapy: Application of pharmacogenetic knowledge of drug metabolism and transport
126. Influence of pharmacogenetics on drug disposition and response
127. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins
128. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)